Here's a recap of the week’s most important stories.
Novo Nordisk's Alhemo (concizumab) receives a positive opinion from the EMA's CHMP for hemophilia A or B with inhibitors. The ...
After hitting a wall with the FDA last year, Novo Nordisk has picked up backing from European drug reviewers for its novel ...
Novo Nordisk’s Alhemo® (concizumab) has been recommended for approval by the European Medicines Agency's (EMA) Committee for ...
Researchers reviewed data from 14 hemophilia patients treated with Sevenfact to better understand its real-world safety and ...
Novo Nordisk's Alhemo drug has been recommended for European approval as a treatment for hemophilia, the company said Friday.
Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...
MyChesCo on MSN3d
FDA Approves Hympavzi for Hemophilia Treatment, Offering Novel Approach to Bleeding Disorder ManagementThe U.S. Food and Drug Administration (FDA) has approved Hympavzi (marstacimab-hncq) for routine prophylaxis aimed at ...
The U.S. Food and Drug Administration (FDA) approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce ...
Marstacimab is a human monoclonal immunoglobulin G type 1 antibody that enhances coagulation by targeting the Kunitz 2 domain of tissue factor pathway inhibitor.
Gene therapy could help obese kids avoid health problems associated with excess weight, including arthritis, a new study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback